Back to Search
Start Over
Antitumor Peptide-Based Vaccine in the Limelight.
- Source :
- Vaccines; Jan2022, Vol. 10 Issue 1, p70-70, 1p
- Publication Year :
- 2022
-
Abstract
- The success of the immune checkpoint blockade has provided a proof of concept that immune cells are capable of attacking tumors in the clinic. However, clinical benefit is only observed in less than 20% of the patients due to the non-specific activation of immune cells by the immune checkpoint blockade. Developing tumor-specific immune responses is a challenging task that can be achieved by targeting tumor antigens to generate tumor-specific T-cell responses. The recent advancements in peptide-based immunotherapy have encouraged clinicians and patients who are struggling with cancer that is otherwise non-treatable with current therapeutics. By selecting appropriate epitopes from tumor antigens with suitable adjuvants, peptides can elicit robust antitumor responses in both mice and humans. Although recent experimental data and clinical trials suggest the potency of tumor reduction by peptide-based vaccines, earlier clinical trials based on the inadequate hypothesis have misled that peptide vaccines are not efficient in eliminating tumor cells. In this review, we highlighted the recent evidence that supports the rationale of peptide-based antitumor vaccines. We also discussed the strategies to select the optimal epitope for vaccines and the mechanism of how adjuvants increase the efficacy of this promising approach to treat cancer. [ABSTRACT FROM AUTHOR]
- Subjects :
- ANTIGENS
TUMOR antigens
IMMUNE checkpoint proteins
PEPTIDES
VACCINES
CLINICAL trials
Subjects
Details
- Language :
- English
- ISSN :
- 2076393X
- Volume :
- 10
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 154884724
- Full Text :
- https://doi.org/10.3390/vaccines10010070